Annual EBITDA:
-$276.74M-$64.75M(-30.54%)Summary
- As of today, XENE annual EBITDA is -$276.74 million, with the most recent change of -$64.75 million (-30.54%) on December 31, 2024.
- During the last 3 years, XENE annual EBITDA has fallen by -$198.65 million (-254.40%).
- XENE annual EBITDA is now -2261.85% below its all-time high of $12.80 million, reached on December 31, 2013.
Performance
XENE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$93.60M-$21.52M(-29.85%)Summary
- As of today, XENE quarterly EBITDA is -$93.60 million, with the most recent change of -$21.52 million (-29.85%) on June 1, 2025.
- Over the past year, XENE quarterly EBITDA has dropped by -$25.13 million (-36.71%).
- XENE quarterly EBITDA is now -1158.16% below its all-time high of $8.85 million, reached on September 30, 2014.
Performance
XENE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$315.53M-$25.13M(-8.66%)Summary
- As of today, XENE TTM EBITDA is -$315.53 million, with the most recent change of -$25.13 million (-8.66%) on June 1, 2025.
- Over the past year, XENE TTM EBITDA has dropped by -$81.81 million (-35.01%).
- XENE TTM EBITDA is now -2306.28% below its all-time high of $14.30 million, reached on September 30, 2014.
Performance
XENE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
XENE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -30.5% | -36.7% | -35.0% |
| 3Y3 Years | -254.4% | -212.6% | -263.1% |
| 5Y5 Years | -596.1% | -10000.0% | -973.7% |
XENE EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -254.4% | at low | -147.8% | at low | -188.8% | at low |
| 5Y | 5-Year | -889.5% | at low | -882.3% | at low | -973.7% | at low |
| All-Time | All-Time | -2261.8% | at low | -1158.2% | at low | -2306.3% | at low |
XENE EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$93.60M(-29.9%) | -$315.53M(-8.7%) |
| Mar 2025 | - | -$72.08M(+6.2%) | -$290.39M(-4.9%) |
| Dec 2024 | -$276.74M(-30.5%) | -$76.84M(-5.3%) | -$276.77M(-9.5%) |
| Sep 2024 | - | -$73.01M(-6.6%) | -$252.77M(-8.2%) |
| Jun 2024 | - | -$68.46M(-17.1%) | -$233.71M(-6.1%) |
| Mar 2024 | - | -$58.45M(-10.6%) | -$220.27M(-4.6%) |
| Dec 2023 | -$211.99M(-66.0%) | -$52.84M(+2.1%) | -$210.51M(-5.0%) |
| Sep 2023 | - | -$53.95M(+1.9%) | -$200.49M(-8.8%) |
| Jun 2023 | - | -$55.02M(-13.0%) | -$184.31M(-15.8%) |
| Mar 2023 | - | -$48.70M(-13.7%) | -$159.22M(-24.9%) |
| Dec 2022 | -$127.74M(-63.6%) | -$42.82M(-13.4%) | -$127.52M(-16.7%) |
| Sep 2022 | - | -$37.77M(-26.2%) | -$109.27M(-25.8%) |
| Jun 2022 | - | -$29.94M(-76.2%) | -$86.89M(-9.7%) |
| Mar 2022 | - | -$16.99M(+30.8%) | -$79.22M(-1.4%) |
| Dec 2021 | -$78.09M(-179.2%) | -$24.57M(-59.6%) | -$78.09M(-17.9%) |
| Sep 2021 | - | -$15.39M(+30.9%) | -$66.24M(-9.7%) |
| Jun 2021 | - | -$22.27M(-40.4%) | -$60.38M(-56.5%) |
| Mar 2021 | - | -$15.86M(-24.7%) | -$38.59M(-25.9%) |
| Dec 2020 | -$27.97M(+29.7%) | -$12.72M(-33.5%) | -$30.66M(-4.3%) |
| Sep 2020 | - | -$9.53M(-1889.1%) | -$29.39M(-2.4%) |
| Jun 2020 | - | -$479.00K(+94.0%) | -$28.71M(+25.7%) |
| Mar 2020 | - | -$7.93M(+30.8%) | -$38.64M(+8.8%) |
| Dec 2019 | -$39.76M | -$11.45M(-29.4%) | -$42.39M(-8.1%) |
| Sep 2019 | - | -$8.85M(+15.0%) | -$39.23M(-2.1%) |
| Jun 2019 | - | -$10.41M(+10.8%) | -$38.42M(-8.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$11.68M(-40.8%) | -$35.44M(-12.8%) |
| Dec 2018 | -$32.54M(-8.3%) | -$8.29M(-3.2%) | -$31.42M(-1.3%) |
| Sep 2018 | - | -$8.04M(-8.1%) | -$31.03M(+1.4%) |
| Jun 2018 | - | -$7.43M(+2.9%) | -$31.47M(+0.9%) |
| Mar 2018 | - | -$7.66M(+3.1%) | -$31.76M(+0.5%) |
| Dec 2017 | -$30.05M(-25.5%) | -$7.90M(+6.7%) | -$31.93M(-8.9%) |
| Sep 2017 | - | -$8.48M(-9.7%) | -$29.32M(-4.7%) |
| Jun 2017 | - | -$7.72M(+1.3%) | -$28.01M(-6.1%) |
| Mar 2017 | - | -$7.82M(-47.7%) | -$26.40M(-10.2%) |
| Dec 2016 | -$23.95M(-187.8%) | -$5.30M(+26.1%) | -$23.95M(-14.2%) |
| Sep 2016 | - | -$7.16M(-17.1%) | -$20.98M(-46.0%) |
| Jun 2016 | - | -$6.12M(-13.8%) | -$14.37M(-85.0%) |
| Mar 2016 | - | -$5.38M(-131.8%) | -$7.77M(-129.0%) |
| Dec 2015 | -$8.32M(-170.3%) | -$2.32M(-315.6%) | -$3.39M(-307.2%) |
| Sep 2015 | - | -$558.00K(-215.3%) | -$833.00K(-109.7%) |
| Jun 2015 | - | $484.00K(+148.4%) | $8.57M(-11.1%) |
| Mar 2015 | - | -$999.00K(-516.3%) | $9.64M(-18.6%) |
| Dec 2014 | $11.84M(-7.5%) | $240.00K(-97.3%) | $11.85M(-17.2%) |
| Sep 2014 | - | $8.85M(+469.6%) | $14.30M(+19.1%) |
| Jun 2014 | - | $1.55M(+28.7%) | $12.01M(+14.9%) |
| Mar 2014 | - | $1.21M(-55.2%) | $10.46M(+13.1%) |
| Dec 2013 | $12.80M(+474.1%) | $2.70M(-58.9%) | $9.25M(+41.1%) |
| Sep 2013 | - | $6.55M | $6.55M |
| Dec 2012 | -$3.42M(+68.2%) | - | - |
| Dec 2011 | -$10.77M | - | - |
FAQ
- What is Xenon Pharmaceuticals Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Xenon Pharmaceuticals Inc.?
- What is Xenon Pharmaceuticals Inc. annual EBITDA year-on-year change?
- What is Xenon Pharmaceuticals Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Xenon Pharmaceuticals Inc.?
- What is Xenon Pharmaceuticals Inc. quarterly EBITDA year-on-year change?
- What is Xenon Pharmaceuticals Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Xenon Pharmaceuticals Inc.?
- What is Xenon Pharmaceuticals Inc. TTM EBITDA year-on-year change?
What is Xenon Pharmaceuticals Inc. annual EBITDA?
The current annual EBITDA of XENE is -$276.74M
What is the all-time high annual EBITDA for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. all-time high annual EBITDA is $12.80M
What is Xenon Pharmaceuticals Inc. annual EBITDA year-on-year change?
Over the past year, XENE annual EBITDA has changed by -$64.75M (-30.54%)
What is Xenon Pharmaceuticals Inc. quarterly EBITDA?
The current quarterly EBITDA of XENE is -$93.60M
What is the all-time high quarterly EBITDA for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. all-time high quarterly EBITDA is $8.85M
What is Xenon Pharmaceuticals Inc. quarterly EBITDA year-on-year change?
Over the past year, XENE quarterly EBITDA has changed by -$25.13M (-36.71%)
What is Xenon Pharmaceuticals Inc. TTM EBITDA?
The current TTM EBITDA of XENE is -$315.53M
What is the all-time high TTM EBITDA for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. all-time high TTM EBITDA is $14.30M
What is Xenon Pharmaceuticals Inc. TTM EBITDA year-on-year change?
Over the past year, XENE TTM EBITDA has changed by -$81.81M (-35.01%)